Skip to main content

Matinas BioPharma Holdings, Inc. (MTNB)

NYSEAMERICAN: MTNB · IEX Real-Time Price · USD
1.09 0.00 (0.00%)
Nov 26, 2021 1:00 PM EST - Market closed
Market Cap235.71M
Revenue (ttm)n/a
Net Income (ttm)-23.54M
Shares Out216.25M
EPS (ttm)-0.11
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume903,186
Open1.07
Previous Close1.09
Day's Range1.04 - 1.13
52-Week Range0.67 - 2.22
Beta2.19
AnalystsBuy
Price Target2.75 (+152.3%)
Earnings DateNov 8, 2021

About MTNB

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nano-crystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid formulation for the treatment of cardiovascular and metabolic ...

IndustryBiotechnology
Founded2013
CEOJerome Jabbour
Employees20
Stock ExchangeNYSEAMERICAN
Ticker SymbolMTNB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for MTNB stock is "Buy." The 12-month stock price forecast is 2.75, which is an increase of 152.29% from the latest price.

Price Target
$2.75
(152.29% upside)
Analyst Consensus: Buy

News

Matinas BioPharma to Participate in 33rd Annual Piper Sandler Virtual Healthcare Conference

BEDMINSTER, N.J., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of crit...

1 week ago - GlobeNewsWire

5 Penny Stocks To Buy According To Analysts With Targets Up To 156%

Penny stocks to buy right now according to analysts. The post 5 Penny Stocks To Buy According To Analysts With Targets Up To 156% appeared first on Penny Stocks to Buy, Picks, News and Information | Pen...

Other symbols:PHUNPROGVERBXERS
1 week ago - PennyStocks

Matinas Biopharma Holdings, Inc. (MTNB) Reports Q3 Loss, Misses Revenue Estimates

Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead f...

2 weeks ago - Zacks Investment Research

Matinas BioPharma Reports Third Quarter 2021 Financial Results and Operational Highlights

– Positive efficacy and safety data announced from first two cohorts of patients in ongoing EnACT study of MAT2203 (oral amphotericin B) for treatment of cryptococcal meningitis; DSMB unanimously recomm...

2 weeks ago - GlobeNewsWire

Matinas Biopharma Holdings, Inc. (MTNB) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Matinas Biopharma Holdings, Inc. (MTNB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 weeks ago - Zacks Investment Research

Matinas BioPharma Selected to Participate in the B. Riley Fall 2021 Growth Biotech Best Ideas Series

BEDMINSTER, N.J., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of crit...

1 month ago - GlobeNewsWire

Matinas BioPharma Initiates Dosing in Phase 1 Study of Potential First Oral Aminoglycoside Antibiotic Drug MAT2501

– Phase 1 study of oral amikacin in healthy volunteers expected to complete in Q1 2022 – – Phase 1 study of oral amikacin in healthy volunteers expected to complete in Q1 2022 –

1 month ago - GlobeNewsWire

Matinas Biopharma Holdings, Inc. (MTNB) Upgraded to Buy: Here's What You Should Know

Matinas Biopharma Holdings, Inc. (MTNB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 month ago - Zacks Investment Research

5 Penny Stocks to Watch That Exploded Today, What You Need to Know

These penny stocks exploded during today's trading session, are they worth watching or not? The post 5 Penny Stocks to Watch That Exploded Today, What You Need to Know appeared first on Penny Stocks to ...

Other symbols:AIHSBESTRNAZRWLK
2 months ago - PennyStocks

Matinas BioPharma Announces Accomplished Biotechnology Executive and Drug Developer Kathryn Penkus Corzo as Nominee t...

– Ms. Corzo brings a 25+ year successful track record in biopharma, excelling in oncology drug development with Takeda, Sanofi Genzyme, and Eli Lilly –

2 months ago - GlobeNewsWire

Matinas BioPharma Announces Webcast of Presentation at the H.C. Wainwright Global Investment Conference

BEDMINSTER, N.J., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, presented a Company overview at ...

2 months ago - GlobeNewsWire

Matinas BioPharma Stock Jumps After Meningitis Candidate Data

Matinas BioPharma Holdings Inc (NYSE: MTNB) has announced positive data from the first two cohorts of the Phase 2 EnACT trial of MAT2203 (oral amphotericin B) for cryptococcal meningitis. The study is s...

2 months ago - Benzinga

Matinas BioPharma Announces Positive Data in the Ongoing EnACT Trial of MAT2203 (Oral Amphotericin B) for the Treatme...

– Step-down therapy with MAT2203 achieved effective clearance of fungal organisms; Mean Early Fungicidal Activity (EFA) was 0.38, exceeding the prespecified primary endpoint threshold target of >0.20 –

2 months ago - GlobeNewsWire

Matinas BioPharma Announces Issuance of U.S. Patent Protecting MAT2203 to Treat or Prevent Cryptococcus Infections

Method-of-use patent strengthens and diversifies MAT2203's long-term patent portfolio Method-of-use patent strengthens and diversifies MAT2203's long-term patent portfolio

3 months ago - GlobeNewsWire

Matinas Biopharma Holdings, Inc. (MTNB) Reports Q2 Loss, Misses Revenue Estimates

Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for th...

3 months ago - Zacks Investment Research

Matinas BioPharma Reports Second Quarter 2021 Financial Results and Operational Highlights

– Enrollment complete in second cohort of EnACT study of MAT2203 (oral amphotericin B) in cryptococcal meningitis; Data and Safety Monitoring Board (DSMB) review of safety and efficacy data from second ...

3 months ago - GlobeNewsWire

Matinas BioPharma to Participate in BTIG Virtual Biotechnology Conference

BEDMINSTER, N.J., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to participate i...

3 months ago - GlobeNewsWire

Matinas BioPharma to Webcast Conference Call Discussing Second Quarter 2021 Financial and Operational Results on Augu...

BEDMINSTER, N.J., July 27, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of crit...

4 months ago - GlobeNewsWire

Best Penny Stocks To Buy? 4 To Watch This Week With Potential Catalysts

Penny stocks to watch with upcoming event dates to keep in mind this week The post Best Penny Stocks To Buy? 4 To Watch This Week With Potential Catalysts appeared first on Penny Stocks to Buy, Picks, N...

Other symbols:CYTRFBIOMBIOMEIPORPH
5 months ago - PennyStocks

Matinas Biopharma Holdings, Inc. (MTNB) Reports Q1 Loss, Misses Revenue Estimates

Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0.00% and -67.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for th...

6 months ago - Zacks Investment Research

Matinas BioPharma Reports First Quarter 2021 Financial Results and Operational Highlights

– Enrollment continues in second cohort of EnACT study of MAT2203 (oral amphotericin b) in cryptococcal meningitis; Data and Safety Monitoring Board (DSMB) evaluation of safety and efficacy data from se...

6 months ago - GlobeNewsWire

Matinas BioPharma Hldgs's Earnings: A Preview

Matinas BioPharma Hldgs (AMEX:MTNB) announces its next round of earnings this Monday, May 10. Here is Benzinga's everything-that-matters guide for this Monday's Q1 earnings announcement.

6 months ago - Benzinga

Matinas BioPharma to Participate in 7th Annual Truist Securities Life Sciences Summit

BEDMINSTER, N.J., April 28, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to participate ...

6 months ago - GlobeNewsWire

Matinas BioPharma to Webcast Conference Call Discussing First Quarter 2021 Financial and Operational Results on May 1...

BEDMINSTER, N.J., April 27, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of cri...

7 months ago - GlobeNewsWire

Matinas BioPharma to Present at the Needham Healthcare Conference

BEDMINSTER, N.J., April 08, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present a Co...

7 months ago - GlobeNewsWire